These findings suggest that PVT1 may be oncogenic and a CCRCC biomarker, and that the PVT1/Mcl-1 pathway may serve as a novel therapeutic target for treating CCRCC. Here, PVT1 is linked to nonpapillary renal cell carcinoma.